These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22511381)

  • 1. Upstream glycoprotein IIb/IIIa inhibitors for STEMI: use on-time or not at all?
    Seto A; Kern MJ
    Catheter Cardiovasc Interv; 2012 May; 79(6):965-6. PubMed ID: 22511381
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
    Feldmann C; Deutsch HJ
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
    [No Abstract]   [Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.
    Fang CC; Jao YT; Chen Y; Yu CL; Wang SP
    Angiology; 2009; 60(2):192-200. PubMed ID: 18445614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.
    De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS
    Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
    Perez de Arenaza D; Bakhai A; Flather M
    N Engl J Med; 2001 Nov; 345(21):1573; author reply 1574-5. PubMed ID: 11794229
    [No Abstract]   [Full Text] [Related]  

  • 9. Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial.
    Timmer JR; ten Berg J; Heestermans AA; Dill T; van Werkum JW; Dambrink JH; Suryapranata H; Ottervanger JP; Hamm C; van 't Hof AW;
    EuroIntervention; 2010 Aug; 6(3):336-42. PubMed ID: 20884411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanical reperfusion: treat well, treat on time too.
    Montalescot G
    Lancet; 2008 Aug; 372(9638):509-10. PubMed ID: 18707968
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
    Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G;
    J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 14. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
    JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ; Kereiakes DJ
    J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes with a pharmacoinvasive strategy: is there a role for glycoprotein IIb/IIIa receptor antagonists?
    Abbott JD; Shah S
    Catheter Cardiovasc Interv; 2011 Sep; 78(3):385-6. PubMed ID: 21976429
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of glycoprotein IIb/IIIa receptor antagonists for patients undergoing percutaneous coronary intervention within twelve hours of fibrinolysis.
    Belle L; Fourny M; Reynaud T; Hammer L; Vanzetto G; Labarère J;
    Catheter Cardiovasc Interv; 2011 Sep; 78(3):376-84. PubMed ID: 21413113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Young JJ
    J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
    [No Abstract]   [Full Text] [Related]  

  • 20. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.